CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
CelLBxHealth plc (CLBX) - Total Assets
Latest total assets as of December 2024: GBX25.46 Million GBX
Based on the latest financial reports, CelLBxHealth plc (CLBX) holds total assets worth GBX25.46 Million GBX as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CelLBxHealth plc - Total Assets Trend (2021–2024)
This chart illustrates how CelLBxHealth plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CelLBxHealth plc - Asset Composition Analysis
Current Asset Composition (December 2024)
CelLBxHealth plc's total assets of GBX25.46 Million consist of 64.5% current assets and 35.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 41.0% |
| Accounts Receivable | GBX774.00K | 3.0% |
| Inventory | GBX1.58 Million | 6.2% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX441.00K | 1.7% |
| Goodwill | GBX2.21 Million | 8.7% |
Asset Composition Trend (2021–2024)
This chart illustrates how CelLBxHealth plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CelLBxHealth plc's current assets represent 64.5% of total assets in 2024, a decrease from 83.2% in 2021.
- Cash Position: Cash and equivalents constituted 41.0% of total assets in 2024, down from 67.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 6.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 8.7% of total assets.
CelLBxHealth plc Competitors by Total Assets
Key competitors of CelLBxHealth plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
CelLBxHealth plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CelLBxHealth plc generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CelLBxHealth plc is currently not profitable relative to its asset base.
CelLBxHealth plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.04 | 5.19 | - |
| Quick Ratio | 4.55 | 4.80 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | GBX13.15 Million | GBX 19.07 Million | - |
CelLBxHealth plc - Advanced Valuation Insights
This section examines the relationship between CelLBxHealth plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.4% |
| Total Assets | GBX25.46 Million |
| Market Capitalization | $941.82 USD |
Valuation Analysis
Below Book Valuation: The market values CelLBxHealth plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CelLBxHealth plc's assets decreased by 18.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CelLBxHealth plc (2021–2024)
The table below shows the annual total assets of CelLBxHealth plc from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX25.46 Million | -18.36% |
| 2023-12-31 | GBX31.18 Million | -37.47% |
| 2022-12-31 | GBX49.87 Million | +5.40% |
| 2021-12-31 | GBX47.31 Million | -- |